Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is focused on rapidly moving experimental therapies towards the clinic.
Our company’s unique strengths include the expertise of our team in discovering and developing products, our lipid nanoparticle delivery system and our focus on product development and expansion.
We’re enthusiastic collaborators. Intellia brings its impressive capabilities plus all the virtues of good partnering: vision, integrity, expertise, reliability and teamwork.
We keep our promises and we are high-science fanatics. We are committed to developing therapies that can address diseases that until now have no cure or even treatment.
Our partners are pioneering biopharmaceutical companies and leading academic institutions – organizations that share our determination to revolutionize medical science.
Our scientific progress and growth are rapid, so there are many opportunities.
We seek strategic collaborators to stretch horizons and unlock the full potential of CRISPR-Cas9 genome editing. Therapeutic areas include:
- Central Nervous System (CNS)
* Some opportunities exist, outside Regeneron partnership
We also pursue alliances for ex vivo and cell-based therapies. Therapeutic areas include:
- Hematological cancers
- Solid tumors
- Auto-/Allo-Immune Disease
- Type 1 DM
- Solid organ rejection
- Regenerative medicine
We constantly scout for cutting-edge technologies that advance the application of CRISPR/Cas9 for human therapeutics and our genome editing platforms, including:
- State-of-the-art delivery technologies
- Novel and/or improved nucleases
- Unique targets
If you are interested in exploring genome editing science and its translation into human therapies, or if your technology could advance the science, please contact us.